Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Immix Biopharma, Inc. before investing.

In this article, we go over a few key elements for understanding Immix Biopharma, Inc.’s stock price such as:

• Immix Biopharma, Inc.’s current stock price and volume
• Why Immix Biopharma, Inc.’s stock price changed recently
• Upgrades and downgrades for IMMX from analysts
• IMMX’s stock price momentum as measured by its relative strength

About Immix Biopharma, Inc. (IMMX)

Before we jump into Immix Biopharma, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Want to learn more about Immix Biopharma, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Immix Biopharma, Inc..

Immix Biopharma, Inc.’s Stock Price as of Market Close

As of June 10, 2025, 12:46 PM, CST, Immix Biopharma, Inc.’s stock price was $2.400.

Immix Biopharma, Inc. is up 2.56% from its previous closing price of $2.340.

During the last market session, Immix Biopharma, Inc.’s stock traded between $2.281 and $2.420. Currently, there are approximately 29.70 million shares outstanding for Immix Biopharma, Inc..

Immix Biopharma, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Immix Biopharma, Inc. Stock Price History

Immix Biopharma, Inc.’s (IMMX) price is currently up 2.56% so far this month.

During the month of June, Immix Biopharma, Inc.’s stock price has reached a high of $3.000 and a low of $1.870.

Over the last year, Immix Biopharma, Inc. has hit prices as high as $3.000 and as low as $1.260. Year to date, Immix Biopharma, Inc.’s stock is up 9.09%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Immix Biopharma, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 09, 2025, there were 0 analysts who downgraded Immix Biopharma, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Immix Biopharma, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Immix Biopharma, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Immix Biopharma, Inc. (IMMX) by visiting AAII Stock Evaluator.

Relative Price Strength of Immix Biopharma, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 09, 2025, Immix Biopharma, Inc. has a weighted four-quarter relative price strength of 8.83%, which translates to a Momentum Score of 83 and is considered to be Very Strong.

Want to learn more about how Immix Biopharma, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Immix Biopharma, Inc. Stock Price: Bottom Line

As of June 10, 2025, Immix Biopharma, Inc.’s stock price is $2.400, which is up 2.56% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Immix Biopharma, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.